Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)

Vera Therapeutics (NASDAQ:VERA) is one of the 17 biotechnology stocks with more than 50% upside.

On January 27, Anupam Rama of JPMorgan maintained an Overweight rating on Vera Therapeutics with a $96 price target. His estimates imply upside of more than 127%.

Rama believes the shares offer strong upside potential from the current trading range. He anticipates that as competitors’ clinical data emerges, the stock price of Vera Therapeutics could rise toward a more appropriate risk-adjusted valuation.

Back on January 16, Cantor Fitzgerald also reiterated its Overweight rating on Vera Therapeutics. Based on a $100 target price, the stock offers nearly 137% upside at the current level.

The firm highlighted that conditions appear favorable for atacicept’s possible approval to treat IgA-related kidney disorder. It also pointed towards the company’s solid foundation for a successful launch, indicating a strong opportunity for market entry once it has obtained regulatory approvals.

Vera Therapeutics is a late-stage clinical biotechnology company that addresses immunological conditions. The company develops and commercializes transformative treatments for serious diseases, including immunoglobulin A nephropathy. It is currently developing MAU868, which is a monoclonal antibody for BK viremia infections in transplant patients.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

This article is originally published at Insider Monkey.